Literature DB >> 11858618

Distribution of cyclosporin A in the cornea after topical or oral administration.

Julian Theng1, Lei Zhou, Donald Tan, Kwok-Wai La.   

Abstract

The purpose of this study was to determine levels of cyclosporin A (CsA) in ocular tissues and fluids after oral or topical administration of CsA in humans requiring immunosuppression for penetrating keratoplasty and to evaluate the sensitivity of a high performance liquid chromatography coupled to electrospray mass spectrometry (LC-MS). High-risk penetrating keratoplasty was performed on 11 patients requiring 5 mg/kg of oral cyclosporin A and 9 patients with topical 0.5% (suspension, equivalent to 5 mg/ml)) preoperative immune suppression. Venous blood samples, as well as aqueous samples, were obtained for some patients, and the central 6.0-8.5 mm corneal buttons were removed and dissected into cornea epithelium, stroma and endothelium and analyzed for CsA levels by LC-MS. The mean values (concentration) of the specimens analyzed (obtained from 11 patients on oral CsA) showed 2.45 +/- 2.12 and 0.35 +/- 0.49 ng CsA/mg tissue in the epithelium and endothelium, respectively. A much smaller concentration, 0.13 +/- 0.14 ng CsA/mg tissue was observed in the stroma. There was a fair amount of CsA in the serum at the time of surgery but no detectable CsA in all aqueous humor samples analyzed. In cases of topical application, the mean concentration of CsA was similarly highest in the epithelium, 64.29 +/- 39.92 ng CsA/mg tissue, followed by the endothelium, 9.98 +/- 6.55 ng CsA/mg tissue, with the lowest levels found in the stroma. Topical application of CsA is able to achieve high levels of CsA in the corneal epithelium, higher than that achieved from oral administration of CsA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11858618     DOI: 10.1089/108076802317233243

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  6 in total

1.  Effect of topical 0.05% cyclosporine A on corneal endothelium in patients with dry eye disease.

Authors:  Consuelo Pérez-Rico; Francisco Germain; María Castro-Rebollo; Agustín Moreno-Salgueiro; Miguel Ángel Teus
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

2.  Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine.

Authors:  B Iaccheri; G Torroni; C Cagini; T Fiore; A Cerquaglia; M Lupidi; S Cillino; H S Dua
Journal:  Eye (Lond)       Date:  2017-02-03       Impact factor: 3.775

Review 3.  Systemic cyclosporine and corneal transplantation.

Authors:  Mohammed Ziaei; Fatemeh Ziaei; Bita Manzouri
Journal:  Int Ophthalmol       Date:  2016-02       Impact factor: 2.031

4.  Cyclosporin A in the ocular fluids of uveitis patients following long-term systemic administration.

Authors:  Paolo Mora; Uta Ceglarek; Francesca Manzotti; Laura Zavota; Arturo Carta; Raffaella Aldigeri; Jelka G Orsoni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-05-06       Impact factor: 3.117

Review 5.  Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.

Authors:  Diane D-S Tang-Liu; Andrew Acheampong
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

Review 6.  Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation.

Authors:  Tulio B Abud; Antonio Di Zazzo; Ahmad Kheirkhah; Reza Dana
Journal:  J Ophthalmic Vis Res       Date:  2017 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.